

CASE LD0275A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ELLIOTT KORSSEN

Type or print name

*Elliott Korsen*

Signature

1-29-04

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SALVATI ET AL.

APPLICATION NO: 10/672,850

FILED: SEPTEMBER 26, 2003

FOR: PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE  
THEREOF FOR THE TREATMENT OF PROLIFERATIVE  
DISORDERS

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-4741



---

Elliott Kersen  
Attorney for Applicants  
Reg. No. 32,705

Date:

*January 29, 2004*

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.  
 LD0275A CIP  
 APPLICATION NO.  
 10/672,850  
 APPLICANT  
 SALVATI ET AL.  
 FILING DATE  
 SEPTEMBER 26, 2003

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,472,389	10/29/02	Ohtani et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 00/12074	3/9/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 00/12497	3/9/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 00/56738	9/28/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Boyce, B.F. et al., "Requirement of pp60 <sup>c-src</sup> Expression for Osteoclasts to Form Ruffled Borders and Resorb Bone in Mice", J. Clin. Invest., Vol. 90, pp. 1622-1627 (1992)
	AS	Campbell, S.L. et al., "Increasing complexity of Ras signaling", Oncogene, Vol. 17, pp. 1395-1413 (1998)
	AT	Du, J. et al., "Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD", American Journal of Physiology, Vol. 269, No. 2, Part 1, pp. C487-C495 (1995)


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
LD0275A CIP  
APPLICATION NO.  
10/672,850  
APPLICANT  
SALVATI ET AL.  
FILING DATE  
SEPTEMBER 26, 2003

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Dudley, D.T. et al., "A synthetic inhibitor of the mitogen-activated protein kinase cascade", Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 7686-7689 (1995)
2AB	Ellis, L.M. et al., "Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for <i>c-src</i> ", The Journal of Biological Chemistry, Vol. 273, No. 2, pp. 1052-1057 (1998)
2AC	Gattone II, V.H. et al., "Epidermal Growth Factor Ameliorates Autosomal Recessive Polycystic Kidney Disease in Mice", Developmental Biology, Vol. 169, pp. 504-510 (1995)
2AD	Henry, J.R. et al., "p38 mitogen-activated protein kinase as a target for drug discovery", Drugs of the Future, Vol. 24, No. 12, pp. 1345-1354 (1999)
2AE	Missbach, M. et al., "A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models in Vivo", Bone, Vol. 24, No. 5, pp. 437-449 (1999)
2AF	Moreland, L.W. et al., "Etanercept Therapy in Rheumatoid Arthritis", Ann. of Intern. Med., Vol. 130, pp. 478-486 (1999)
2AG	Nauta, J. et al., "Biliary Epithelial Cells from Mice with Congenital Polycystic Kidney Disease Are Hyperresponsive to Epidermal Growth Factor", Pediatric Research, Vol. 37, No. 6, pp. 755-763 (1995)
2AH	Nistér, M. et al., "Differential Expression of Platelet-derived Growth Factor Receptors in Human Malignant Glioma Cell Lines", The Journal of Biological Chemistry, Vol. 266, No. 25, pp. 16755-16763 (1991)
2AI	O'Reilly, M.S. et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", Cell, Vol. 79, pp. 315-328 (1994)
2AJ	O'Reilly, M.S. et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", Nature Medicine, Vol. 2, No. 6, pp. 689-692 (1996)
2AK	O'Reilly, M.S. et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth", Cell, Vol. 88, pp. 277-285 (1997)
2AL	Rankin, E.C.C. et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", British Journal of Rheumatology, Vol. 34, pp. 334-342 (1995)
2AM	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases", Current Medical Chemistry, Vol. 6, pp. 807-823 (1999)
2AN	Sato, T.N. et al., "Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation", Nature, Vol. 376, pp. 70-74 (1995)

**EXAMINER**


**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

ATTY. DOCKET NO.  
LD0275A CIP  
APPLICATION NO.  
10/672,850  
APPLICANT  
SALVATI ET AL.  
FILING DATE  
SEPTEMBER 26, 2003

Group



(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Schwartzberg, P.L., "The many faces of Src: multiple functions of a prototypical tyrosine kinase", Oncogene, Vol. 17, pp. 1463-1468 (1998)
3AB	Seger, R. et al., "The MAPK signaling cascade", FASEB J., Vol. 9, pp. 726-735 (1995)
3AC	Sivaraman, V.S. et al., "Hyperexpression of Mitogen-activated Protein Kinase in Human Breast Cancer", J. Clin. Invest., Vol. 99, No. 7, pp. 1478-1483 (1997)
3AD	Soriano, P. et al., "Targeted Disruption of the c-src Proto-Oncogene Leads to Osteopetrosis in Mice", Cell, Vol. 64, pp. 693-702 (1991)
3AE	Staley, C.A. et al., "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for c-Src", Cell Growth and Differentiation, Vol. 8, pp. 269-274 (1997)
3AF	Strawn, L.M. et al., "Inhibition of Glioma Cell Growth by a Truncated Platelet-derived Growth Factor- $\beta$ Receptor", The Journal of Biological Chemistry, Vol. 269, No. 33, pp. 21215-21222 (1994)
3AG	Wilson, P.D. et al., "Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease", European Journal of Cell Biology, Vol. 61, pp. 131-138 (1993)
3AH	
3AI	
3AJ	
3AK	
3AL	
3AM	
3AN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.